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Objective.Toevaluate gastrointestinal and cardiovascular adverse event risks associatedwithoptical colonoscopy
(OC) amongMedicare outpatients who received computed tomography colonography (CTC) as their initial method
of colorectal evaluation. Methods.Medicare claims were compared between 6114 outpatients ≥66 years who
received initial CTC and 149,202 outpatients who received initial OC between January 2007 and December 2008.
OC patients werematched on county of residence and year of evaluation. Outcomes included lower gastrointestinal
bleeding, gastrointestinal perforation, other gastrointestinal events and cardiovascular events resulting in an
emergency department visit or hospitalization within 30 days. Results. Among 1000 outpatients undergoing
initial CTC, 12.4 experienced lower gastrointestinal bleeding, 0.7 perforation, 18.0 other gastrointestinal events
and 45.5 cardiovascular events within 30 days. After multivariate adjustment, risks of lower gastrointestinal
bleeding, other gastrointestinal events and cardiovascular events were higher with initial OC than CTC, with
or without subsequent OC (Odds Ratio 1.91 95 Conﬁdence Interval [1.47,2.49], Odds Ratio 1.35 95 Conﬁdence
Interval [1.07,1.69] and Odds Ratio 1.38 95 Conﬁdence Interval [1.18,1.62], respectively); however, perforation
risk did not differ (p = 0.10). This pattern is similar in older and symptomatic populations. Conclusion. Rates of
gastrointestinal bleeding, other gastrointestinal events and cardiovascular events are lower following initial CTC
than OC, but rates of perforation do not differ.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
CT colonography (CTC) is an alternative to optical colonoscopy (OC)
for colorectal evaluation, including cancer screening and diagnostic
evaluation. Although CTC demonstrates a per patient sensitivity of
0.78 in the detection of adenomas at least 6mm, and anoverall sensitivity
of 89% in the detection of polyps at least 6mm in diameter (Johnson et al.,
2008; Pickhardt et al., 2003) it may be safer than OC given that CTC does
not involve passage of an endoscope or require sedation. Prior case series
suggest low rates of gastrointestinal perforation and chest pain amongphy; OC, optical colonoscopy.
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. This is an open access article underpatients who receive CTC; particularly in the screening population
(Pickhardt, 2006; Burling et al., 2006; Atkin et al., 2013). However,
there is a paucity of population based studies directly evaluating the
risk of adverse events following CTC among the elderly where the risks
are thought to be higher (Sosna et al., 2006; Rabeneck et al., 2008;
Singh et al., 2010; Warren et al., 2009; Rutter et al., 2012; Day et al.,
2011; Sharma et al., 2007). This lack of data about the risks and beneﬁts
of CTC in the older population, in addition to concerns over the cost
effectiveness of this modality, was cited in the Centers for Medicare
and Medicaid Services (CMS) decision to deny coverage for screening
CTC inMarch2009 (Knudsen et al., 2010;MEDCAC transcript Computed
Tomography Colonography, 2008).
Given this background, our objective was to evaluate the risks of
gastrointestinal and cardiovascular events among symptomatic and
asymptomatic outpatient Medicare beneﬁciaries who received CTC as
theirﬁrstmethod of colorectal evaluation during the twoyears preceding
this CMS coverage determination; January 2007 throughDecember 2008.
Adverse events known to be associated with OC were selected as OC is
the traditional method of colorectal evaluation. We focused on patients
undergoing initial CTC to capture adverse events attributable to the CTC
and to any subsequent testing within 30 days (including OC with orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2006)) driven by the ﬁndings of the CTC. To provide clinical context
CTC patients were compared to a cohort of patients who received initial
OC andalso stratiﬁed by asymptomatic (i.e. screening) and symptomatic
(i.e. diagnostic) indications (Pickhardt, 2006; Atkin et al., 2013).
Materials & methods
Design overview
This Health Insurance Portability and Accountability Act compliant
study using de-identiﬁed Medicare claims data was exempt from institu-
tional review board approval. We performed a retrospective cohort study
of all Medicare beneﬁciaries ≥66 years of age in the United States with a
claim for CTCbetween January 2007 andDecember 2008 and a randomly selected
groupof patientswith a claim forOCduring the same timeperiod,matched9:1 by
county of residence and year of colorectal evaluation. Approximately 98% of
adults in the United States ages 65 and older are enrolled in Medicare, making
Medicare data a robust source of health care utilization (RDA Center, 2012).
Adverse events resulting in an emergency department visit or inpatient admission
30 days following either procedure were determined from Medicare Provider
Analysis and Review, Outpatient and Carrier ﬁles using appropriate Current
Procedural Terminology/Healthcare Common Procedure Coding System
(CPT/HCPCS) and International Classiﬁcation of Disease, Ninth Edition, Clinical
Modiﬁcation (ICD-9-CM) codes (e-Table 1). We used a 30 day time interval for
the assessment of complications to ensure a comparable follow-up interval in
both cohorts based on prior data about complications from OC (Warren et al.,
2009). Claims were also used to identify comorbidities associated with increased
likelihood of adverse events in the year preceding either CTC or OC and
comparable adverse events in the preceding 90 days. The analysis focused on pa-
tients who had either initial CTC, deﬁned as no OC on the same day or within the
prior 12 months, or initial OC, deﬁned as no OC within the prior 12 months. Al-
though 14% of the initial CTC patients in our study underwent OC within the
12 months after CTC, similar to published rates of 13–15% in the literature (Kim
et al., 2010;Macari et al., 2011), only 3% (187/6114) of initial CTCpatients received
OC within 30 days. Due to this small sample size a separate analysis of adverse
events amongpatientswho receivedOCwithin 30days of CTCwasnot performed.
However, additional analyses stratiﬁed patients by asymptomatic (i.e. screening)
and symptomatic (i.e. diagnostic) indications using ICD-9 codes from the CTC or
OC claim, based on a previously utilized algorithm (Ko et al., 2010; Zafar et al.,
2013); a full list of codes is provided in e-Table 1.
Setting and participants
We excluded patients (a) enrolled in a Medicare Health Maintenance
Organization within the year preceding or 30 days following CTC (n = 7429);
or (b) disenrolled from Medicare Part A or B coverage during the same time
interval (n = 558). Similar to prior methodology (Warren et al., 2009), we
excluded patients with a signiﬁcant prior colonic disease that increased the
risk of perforation including Crohn's disease or ulcerative colitis (n = 2067),
prior colorectal cancer (n = 6385), or diverticulitis in the preceding year
(n = 11,169). Because the objective of our study was to evaluate patients
who received CTC as the ﬁrst method of colorectal evaluation we excluded
patients who received CTC with OC either in the prior 12 months (n = 3595)
or on the same day (n= 3197). Similarly, OC patients who received OC within
the prior 12 monthswere excluded (n= 1994).We also excludedpatientswith
more than one OC within 30 days of the initial OC or CTC (n = 6). Eighteen
patients were excluded for CTC claims in the year preceding OC or CTC and
thirteen patients were excluded for incomplete billing data. No patients
were excluded on the basis of an incomplete procedure. The ﬁnal study
population was comprised of 153,316 patients (Fig. 1). These 153,316 patients
included 3609 CTC and 115,691 OC patients from a prior publication (Zafar
et al., 2013). Differences in study populations are due to inclusion and/or
exclusion criteria stemming from the disparate foci of these publications.
Outcomes and follow-up
Four groups of adverse events requiring emergency department visits or
inpatient admissions were identiﬁed in the 30 days following either procedure:
lower gastrointestinal bleeding or administration of blood transfusions (excludingpatientswith transfusions performed 90days prior to either procedure), gastro-
intestinal perforation, other gastrointestinal events (paralytic ileus, nausea,
vomiting and dehydration, abdominal pain), and cardiovascular events (myocar-
dial infarction or angina; arrhythmias; congestive heart failure [CHF]; cardiac or
respiratory arrest; or syncope, hypotension, or shock). These adverse events
were chosen as they have been associated with complications of OC, which is
the traditional method of colorectal evaluation. Similar adverse events in the
90 days preceding CTC or OC were also recorded. Death within 30 days was
evaluated, although cause of death cannot be inferred from claims data.
We accounted for common comorbidities associated with these adverse
events using claims data from the year preceding CTC or OC including: atrial
ﬁbrillation/ﬂutter, congestive heart failure,chronic pulmonary disease, stroke,
diabetes, renal failure, diverticulosis, and obesity (Rabeneck et al., 2008;
Warren et al., 2009; Lohsiriwat, 2010).
Sociodemographic characteristics including gender, age, and race were
obtained frombeneﬁciary summaryﬁles. Agewas categorized into three groups
(66–74, 75–84, and≥85 years) and race intoﬁve groups (White, Black, Hispanic,
Asian, and other).
Statistical analysis
Chi-square analysis was used to compare sociodemographic and clinical
characteristics, unadjusted risks of adverse events, and mortality within
30 days between patients who received initial CTC and OC. Unadjusted
risks of adverse events were included as these data have not been previously
reported using claims data. Given the cohort study design a generalized linear
regression with a logit link and binomial distribution was used to estimate the
odds ratios (OR) of adverse events between patients undergoing CTC and OC by
indication (i.e. symptomatic versus asymptomatic) controlling for differences in
patient characteristics including gender, age, race, comorbidities associated with
studied adverse events, and adverse events in the preceding 90 days. Due to
low event rates for the targeted adverse events there is limited concern of
overestimation of the risk ratio, which is approximated by the OR in cohort
studies. Statistical signiﬁcance was declared for results with a two-sided p-value
of b0.05. We used STATA, version 11 (STATA Corp) for all statistical analyses.
Results
The ﬁnal cohort included 6114 initial CTC outpatients with a mean
age of 76.7 years (age range, 66–103 years; 2223 males [mean age 77;
age range 66–96]; 3891 females [mean age 77; age range 66–103])
and 149,202 initial OC outpatients with a mean age of 74.4 years (age
range, 66–104 years; 67,586 males [mean age 74; age range 66–101];
81,616 females [mean age 75; age range 66–104]). Women, patients
N75 years of age and Whites were more likely to receive CTC as their
initial method of colorectal evaluation than OC (Table 1). Patients
undergoing initial CTC had a higher prevalence of comorbidities than
patients undergoing initial OC, except for diabetes, diverticulosis and
obesity. Among patients referred to initial CTC, with or without OC in
the subsequent 30 days, the unadjusted risk of lower gastrointestinal
bleeding per 1000 patients was 12.4, of perforation was 0.7, of other
gastrointestinal events was 18.0 and of cardiovascular events was
45.5. Of note, perforation rates were low in both cohorts (4/6114
[0.7%] initial CTC and 181/149,202 [1.2%], initial OC). Similar proportions
of patients died within 30 days in both cohorts.
Multivariate regression was performed to account for differences in
gender, age, race, comorbidities associated with adverse events, and
adverse events in the preceding 90 days. This revealed a higher risk of
lower gastrointestinal bleeding, other gastrointestinal events and
cardiovascular events among patients who underwent initial OC
compared to initial CTC in the subsequent 30 days (OR 1.91 95CI
[1.47,2.49], OR 1.35 95CI [1.07,1.69] and OR 1.38 95CI [1.18,1.62],
respectively), but no difference in the risk of perforation (Table 2).
Similarly, even with adjustment for age, patients greater than 75 years
who received either CTC or OC demonstrated a higher risk of lower
gastrointestinal bleeding, other gastrointestinal events, and cardiovascu-
lar events than patients less than 75 years (OR 2.98 95CI [2.61,3.41], OR
1.39 95CI [1.26,1.53], and OR 1.44 95CI [1.33,1.55], respectively).
Fig. 1. Study population.
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presence of symptoms. Higher unadjusted adverse event rates per
1000 patients were demonstrated among thosewith symptoms relative
to those without symptoms within both cohorts (Table 3). Following
adjustment for gender, age, race, comorbidities associated with adverse
events, and adverse events in the preceding 90 days, symptomatic
patients referred to initial OC were found to have higher adjusted
rates of lower gastrointestinal bleeding, other gastrointestinal events
and cardiovascular events compared to symptomatic patients referred
to initial CTC, with or without OC in the subsequent 30 days (OR 1.92
95CI [1.47, 2.51], OR 1.35 95CI [1.07,1.70], OR 1.43 95CI [1.22, 1.68],
respectively) (Table 4). Again, even with adjustment for age, higher
rates of lower gastrointestinal bleeding, other gastrointestinal events
and cardiovascular events were demonstrated among symptomatic
patients greater than 75 years compared to patients less than 75 years
(OR 2.70 95CI [2.43,3.21], OR 1.77 95CI [1.53,2.05], OR 2.37 95CI
[2.14,2.63], respectively) (Table 4). A similar pattern was observed
within the asymptomatic cohort, but did not reach signiﬁcance.
Discussion
Our study demonstrates that patients ≥66 years of age who undergo
initial CTC, with or without subsequent OC within 30 days, have lowerrisks of lower gastrointestinal bleeding, other gastrointestinal events
and cardiovascular events compared to patients who undergo initial OC.
However, the risk of perforation does not differ between initial CTC and
OC. This pattern is similar among symptomatic, asymptomatic and older
patients, although it did not reach signiﬁcance for asymptomatic patients.
The ﬁndings in this population based study differ somewhat from
prior case series demonstrating lower unadjusted rates of perforation
among patients who undergo CTC (0.00–0.05%) (Pickhardt, 2006; Kim
et al., 2007) andof cardiovascular events (0.05–0.06 per 1000 diagnostic
CTC procedures) (Pickhardt, 2006; Burling et al., 2006). Differences in
our results may reﬂect limitations of prior study populations, follow
up interval, or measurement approach. Alternatively, these ﬁndings
may reﬂect the small number of perforations identiﬁed in our
study; particularly within the CTC cohort. Although we used the same
methodology to identify perforations in both cohorts (i.e., emergency
department visits and hospitalizations), CTC is more sensitive to
sub-clinical perforation than OC due to the ability to visualize small
amount of pneumoperitoneum (Pendse and Taylor, 2013). It is
reassuring that our results are similar to perforation rates from a
study where patients with pneumoperitoneum on CTC were referred
to the emergency department (0.6 per 1000 CTC procedures) (Sosna
et al., 2006), which resembles our measurement approach. Our
results also extend the previously published literature about the
Table 1
Frequency of Medicare outpatient characteristics and unadjusted adverse events within
30 days of receiving initial CT colonography (CTC) or initial optical colonoscopy (OC)
between January 2007 and December 2008, (%).
Initial CTC Initial OC p
value
(n = 6114) (n = 149,202)
Gender b .001
Male 2223 (36.4) 67,586 (45.3)
Female 3891 (63.6) 81,616 (54.7)
Age b .001
66–74 2500 (40.9) 82,411 (55.2)
75–84 2700 (44.2) 55,893 (37.5)
≥85 914 (14.9) 10,898 (7.3)
Race b .001
White 5688 (93.0) 130,481 (87.5)
Black 239 (3.9) 10,133 (6.8)
Other a 78 (1.3) 2946 (2.0)
Asian 52 (0.9) 3197 (2.1)
Hispanic 57 (0.9) 2445 (1.6)
Comorbidities associated with adverse events
Atrial ﬁbrillation/ﬂutter 1610 (26.3) 18,813 (12.6) b .001
Congestive heart failure 1298 (21.2) 19,735 (13.2) b .001
Chronic pulmonary disease 1759 (28.8) 34,149 (22.9) b .001
Diabetes 1729 (28.3) 45,040 (30.2) 0.001
Stroke 1419 (23.2) 24,457 (16.4) b .001
Renal disease 636 (10.4) 12,827 (8.6) b .001
Diverticulosis 2617 (42.8) 85,437 (57.3) b .001
Obesity 298 (4.9) 8010 (5.4) 0.092
Unadjusted adverse events within 30 days
(risk per 1000 Medicare beneﬁciaries)
Gastrointestinal bleeding/transfusion 76 (12.4) 2471 (16.6) 0.013
Perforation 4 (0.7) 181 (1.2) 0.214
Other GI 110 (18.0) 2692 (18.0) 0.997
Paralytic ileus 11 (1.8) 573 (3.8) 0.011
Nausea, vomiting or dehydration 75 (12.3) 1721 (11.4) 0.623
Abdominal pain 34 (5.6) 695 (4.7) 0.311
Cardiovascular disease 278 (45.5) 5167 (34.6) b .001
MI or angina b 49 (8.0) 1112 (7.5) 0.617
Arrhythmias 148 (24.2) 2754 (18.5) 0.001
CHF 119 (19.5) 1874 (12.6) b .001
Cardiac or respiratory arrestc 28 (4.6) 544 (3.6) 0.238
Syncope, hypotension or shock 49 (8.0) 945 (6.3) 0.106
Mortality
Death within 30 days 21 (0.3) 499 (0.3) 0.905
a Other includes Unknown and Native American.
b Including chest pain.
c Not including shortness of breath.
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are the ﬁrst study to assess the risk of lower gastrointestinal bleeding
following CTC.
Given that clinicians and patients desire data on the risks of initial
CTC relative to initial OC, we have provided comparative data between
these two procedures. Our analyses suggest that patients who undergo
initial CTC, with or without subsequent OC, may experience lower rates
of serious gastrointestinal, other gastrointestinal and cardiovascularTable 2
Regression analysis of adverse events among Medicare outpatients who received initial CT colo
2008a.
Gastrointestinal bleed Perforatio
OR 95% CI OR
Total population (n = 155,316)
Type of examination
Initial CTC (n = 6114)
Initial OC (n = 149,202) 1.91 [1.47,2.49] 2.62
Age 66–74 (ref)
75–84 1.38 [1.24,1.53] 1.18
≥85 2.98 [2.61,3.41] 0.75
a Regression analyses are adjusted for gender, age, race, comorbidities associatedwith adver
diabetes, stroke, renal disease, diverticulosis, obesity), and adverse events in preceding 90 dayevents compared to patients who receive initial OC. This ﬁnding is
intuitively reasonable, given that CTC does not require sedation and
the intention of CTC is to selectively refer the approximately 8–15% of
patients with suspected clinically signiﬁcant polyps (N6 mm) and
masses to OC for further evaluation (Kim et al., 2007, 2010; Macari
et al., 2011). However, it is important to recognize that we were unable
to fully adjust for differences between the groups based upon the
information available in claims data. Patients who receive CTC are
generally sicker than patients who receive OC (Zafar et al., 2013).
Furthermore, given the standard CTC technique,which does not include
intravenous contrast, the use of a 30 day time interval is conservative
and may include adverse events not directly related to this procedure.
As such, our results may underestimate the differences between these
two examinations.
Even after adjustment, we found that the risk of adverse events
following CTC depends upon patient age (comparing patients 75 and
older to patients under 75). Higher risk of lower gastrointestinal bleeding
and cardiovascular events among patients older than 75 years who
undergo colorectal evaluation are concordant with prior studies
evaluating OC (Rabeneck et al., 2008; Singh et al., 2010; Warren et al.,
2009; Rutter et al., 2012), but has not previously been demonstrated
for CTC. Both the US Preventive Services Task Force and the American
College of Physicians recommend against routine screening of patients
older than 75 due to increased risk of complications, competing causes
of mortality and demonstrated beneﬁt at least 7 years after screening
(Qaseem et al., 2012; Whitlock et al., 2008). Our ﬁndings support the
inclusion of CTC in these recommendations.
Our study has several limitations. We used billing codes from Medi-
care claims rather than medical record review to determine adverse
events. No studies validating the use of billing claims for CTC have been
reported. However, prior studies have demonstrated high sensitivity
and speciﬁcity for the assessment of procedures, including endoscopy,
using Medicare claims compared to medical charts (Schenck et al.,
2007; Ko et al., 2011; Javitt et al., 1993) and high likelihood of identifying
diagnoses and select adverse events in Medicare claims (Fowles et al.,
1995). It is reassuring that our unadjusted adverse event risks among
the OC cohort are similar to prior studies (Warren et al., 2009). We did
not perform a randomized control trial, and there are likely to be unmea-
sured confounders or selection effects that we were unable to include in
our adjustments. The technique utilized for CTC cannot be derived from
claims data but is potentially important given that manual insufﬂation,
luminal disease and use of a rectal balloon are associatedwith perforation
(Pickhardt, 2006; Burling et al., 2006; Sosna et al., 2006; Pendse and
Taylor, 2013). Some of the adverse events speciﬁc to CT, such as radiation
risk, cannot be measured with claims data. Although our ﬁndings may
not generalize to younger patients, colorectal cancer is predominantly a
disease of the elderly.
In conclusion, our study demonstrates that adverse event rates
following initial CTC among the elderly are low, with the greatest




95% CI OR 95% CI OR 95% CI
[0.84,8.22] 1.35 [1.07,1.69] 1.38 [1.18,1.62]
[0.84,1.66] 1.39 [1.26,1.53] 1.44 [1.33,1.55]
[0.38,1.46] 1.87 [1.63,2.15] 2.54 [2.29,2.80]
se events (i.e. atrial ﬁbrillation/ﬂutter, congestive heart failure, chronic pulmonary disease,
s.
Table 3
Unadjusted risk per 1000Medicare outpatients for adverse events within 30 days of initial CT colonography (CTC) or initial optical colonoscopy (OC) received between January 2007 and
December 2008 by indication.
Initial CTC Initial OC
Asymptomatic Symptomatic Asymptomatic Symptomatic
(n = 1384) (n = 4730) (n = 54,039) (n = 95,163)
Events Events Events Events
(n) Risk (n) Risk (n) Risk (n) Risk
Gastrointestinal bleeding 4 2.9 72 15.2 371 6.9 2100 22.1
Perforation 1 0.7 3 0.6 46 0.9 135 1.4
Other GI 5 3.6 105 22.2 311 5.8 2381 25
Ileus 0 0 11 2.3 76 1.4 497 5.2
Nausea, vomiting or dehydration 4 2.9 71 15 169 3.1 1552 16.3
Abdominal pain 2 1.4 32 6.8 107 2 588 6.2
CVD events 26 18.8 252 53.3 610 11.3 4557 47.9
MI or anginaa 4 2.9 45 9.5 176 3.3 936 9.8
Arrhythmias 14 10.1 134 28.3 329 6.1 2425 25.5
CHF 5 3.6 114 24.1 94 1.7 1780 18.7
Cardiac or respiratory arrest b 1 0.7 27 5.7 43 0.8 501 5.3
9 6.5 40 8.5 149 2.8 796 8.4
a Including chest pain.
b Not including shortness of breath.
Table 4
Regression analysis of adverse events among Medicare outpatients who received initial CT colonography (CTC) or initial optical colonoscopy (OC) between January 2007 and December
2008 by indicationa.
Gastrointestinal bleed Perforation Other gastrointestinal
events
Cardiovascular events
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Asymptomatic population (n = 55,423)
Type of examination
Initial CTC (n = 1384)
Initial OC (n = 54,039) 2.29 [0.76,6.90] 3.53 [0.20,63.54] 2.36 [0.89,6.30] 1.22 [0.74,2.01]
Age 66–74 (ref)
75–84 1.14 [0.87,1.48] 1.02 [0.49,2.14] 0.92 [0.70,1.22] 1.35 [1.10,1.64]
≥85 1.49 [0.81,2.75] 1.99 [0.45,8.69] 1.22 [0.68,2.20] 1.56 [1.05,2.32]
Symptomatic population (n = 99,893)
Type of examination
Initial CTC (n = 4730)
Initial OC (n = 95,163) 1.92 [1.47,2.51] 2.55 [0.73,8.94] 1.35 [1.07,1.70] 1.43 [1.22,1.68]
Age 66–74 (ref)
75–84 1.36 [1.21,1.52] 1.20 [0.81,1.79] 1.40 [1.26,1.56] 1.38 [1.27,1.50]
≥85 2.79 [2.43,3.21] 0.67 [0.33,1.37] 1.77 [1.53,2.05] 2.37 [2.14,2.63]
a Regression analyses are adjusted for gender, age, race, comorbidities associatedwith adverse events (i.e. atrial ﬁbrillation/ﬂutter, congestive heart failure, chronic pulmonary disease,
diabetes, stroke, renal disease, diverticulosis, obesity), and adverse events in preceding 90 days.
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lower following initial CTC, with or without subsequent OC, than fol-
lowing initial OC; similar rates of perforation may stem from the
small number of perforations in both cohorts. A similar pattern was
demonstrated among patients N75 years of age and those with
symptoms referable to colorectal cancer. These data can help prima-
ry care providers and patients seeking to understand complications
associated with these methods of colorectal cancer screening and
targeted diagnostic evaluation.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.pmedr.2014.08.001.
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